Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625840 · ClinicalTrials.gov registry record · Phase 1
A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06625840 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 16 participants.
The verdict
NCT06625840, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The goal of this study is to learn how safe MK-1167 is in healthy elderly adults and how well people tolerate it.
Interventions
- DRUG Placebo
- DRUG MK-1167
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-09-18 |
| Est. Completion | 2024-05-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06625840
The ClinicalTrials.gov registry entry for NCT06625840 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06625840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06625840 about?
NCT06625840 is a clinical study titled "A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)". The goal of this study is to learn how safe MK-1167 is in healthy elderly adults and how well people tolerate it.
What is the current status of trial NCT06625840?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-09-18. Estimated completion is 2024-05-08.
What interventions are being tested in trial NCT06625840?
The interventions under investigation include: Placebo (DRUG), MK-1167 (DRUG).
Who is sponsoring clinical trial NCT06625840?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.